Rockefeller Capital Management
NRIX icon

Rockefeller Capital Management’s Nurix Therapeutics NRIX Stock Holding History

Rockefeller Capital Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$82.4K Buy
5,318
+4,250
+398% +$70.5K ﹤0.01% 2986
2025
Q4 		$20.3K Buy
+1,068
New +$15.3K ﹤0.01% 3517
2023
Q1 		– Sell
-385
Closed -$4K – 3236
2022
Q4 		$4K Buy
385
+328
+575% +$3.96K ﹤0.01% 3385
2022
Q3 		$0 Hold
57
– – ﹤0.01% 4223
2022
Q2 		$0 Buy
+57
New +$646 ﹤0.01% 4304

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Rockefeller Capital Management's NRIX Position: Q1 2026 in Review

Rockefeller Capital Management increased its Nurix Therapeutics (NRIX) stake by 398% in Q1 2026, buying an estimated $70.5K and bringing the position to 5,318 shares worth $82.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2986.

Rockefeller Capital Management first reported a position in NRIX in Q2 2022 and has held it in 5 quarters since. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Rockefeller Capital Management held 5,318 shares of Nurix Therapeutics worth $82.4K as of Q1 2026.
  • Rockefeller Capital Management bought 4,250 Nurix Therapeutics shares in Q1 2026, an estimated $70.5K.
  • Nurix Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #2986 holding.
  • Rockefeller Capital Management first reported a position in Nurix Therapeutics in Q2 2022 and has held it in 5 quarters since.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.